Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Alogliptin/Pioglitazone on Beta-cell Function in Type 2 Diabetes
NCT02823808Phase 4Unknown
- Sponsor
- Kyung Hee University Medical Center
- Start
- Jul 2017
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of alogliptin and pioglitazone in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kyung Hee University Medical Center. Primary endpoint: Cumulative treatment failure (HbA1c≥7.0%) rate for glycemic control at 104 weeks. Status: unknown.
02
Drugs
alogliptinpioglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02823808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02823808.